Ojemda
Payments companies reported to CMS as associated with Ojemda. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Ojemda, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Ojemda
These are the largest totals companies reported as associated with Ojemda. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Samuel Blackman | Philadelphia, PA | Pediatric Hematology-Oncology | $246,570.23 |
| Caroline Hastings | Oakland, CA | Pediatric Hematology-Oncology | $92,922.36 |
| Daniel Landi | Durham, NC | Pediatrics | $61,379.88 |
| Mohamed Abdelbaki | Saint Louis, MO | Pediatric Hematology-Oncology | $44,740.99 |
| Amy Smith | Orlando, FL | Pediatric Hematology-Oncology | $42,730.27 |
| Betty Herrington | Jackson, MS | Pediatric Hematology-Oncology | $21,966.29 |
| Alok Jaju | Phoenix, AZ | Pediatric Radiology | $15,000.00 |
| Shannon Raber | San Francisco, CA | Pediatrics (Nurse Practitioner) | $14,053.40 |
| Stephanie Toll | Los Angeles, CA | Pediatrics | $12,743.18 |
| Cassie Kline | Philadelphia, PA | Pediatric Hematology-Oncology | $12,230.24 |
Prescribed Ojemda?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.